BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: Pharma
.jpg)
STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: FDA’s Woodcock, other experts highlight persistent issues plaguing pharma, biotech in the wake of Covid-19
WASHINGTON — Current and former government officials proffered a clear eyed, and often depressing, take…
STAT+: FTC challenges several big drugmakers over inaccurate or improper patent listings
Making good on a recent threat, the U.S. Federal Trade Commission is challenging more than…
.jpg)
STAT+: FDA cites cancer links in seeking to withdraw approval of antibiotic used in pigs
After years of trying, the U.S. Food and Drug Administration is again seeking to withdraw…
STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines
Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value…
XBI biotech index rises, giving investors a shred of hope
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Pharma trade group slams European Commission proposal; U.S. lawmakers demand FDA explain its approach to shortages
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Shrinking COVID vaccine sales has Moderna course-correcting
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Health plan formularies lowered barriers to fair access to some drugs, analysis finds
Most of the formularies run by some of the largest health plans in the U.S….
STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Nostrum Laboratories and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates
A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising…
STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Gene editing has had a big week in the spotlight. Here’s what’s going on
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug
As Medicare prepares to negotiate prices for its first batch of medicines, an advocacy group…
Sarepta’s disappointing data put the FDA in a difficult spot
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease
The Food and Drug Administration is convening a meeting of outside experts on Tuesday to…
Your Monday morning biotech news roundup
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: FDA flags safety concerns with CRISPR-based sickle cell treatment; FDA warns about eye drop infection risk
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Paying for Covid pills will soon shift to insurers
WASHINGTON — The Biden administration is slowly shifting millions of Covid-19 treatments to private insurers…
STAT+: Why Sanofi got shellacked
Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion…
STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer
And so, another working week will soon draw to a close. Not a moment too…
STAT+: FDA approves Lilly ulcerative colitis treatment with a new approach to tamping down inflammation
The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a…
Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Eisai reports injectable version of Alzheimer’s drug as effective as IV; Pfizer says combo flu and Covid shot shows strong response
Hello, everyone, and how are you this morning? We are doing just fine, thank you,…
STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds
Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies,…
STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show
A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler,…
STAT+: Europe takes steps to head off drug shortages, even as U.S. proposals stall
European drug regulators are updating regulations to stem drug shortages. Are there lessons for Americans?…
STAT+: Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee
Novartis has gone to court to gain access to Takeda Pharmaceutical documents over concerns that…
The XBI biotech index hit its lowest point since 2018. No one knows what comes next.
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Pharma likely to expand legal attacks on Medicare negotiations; CDC recommends rationing RSV drug
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: With an old approach but new energy, ADCs take center stage as promising cancer treatments
MADRID — If you had to pinpoint one subject that stood out at this year’s…
Why AstraZeneca’s CEO is accusing British tabloids of ‘fake news’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: ‘Missed opportunities’: Why a U.K. government plan to disclose financial ties between pharma and docs may fall short
Earlier this month, the U.K. government issued a proposal to gather information and opinions about…
STAT+: Results on Novartis prostate cancer therapy could expand its use
MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic…
STAT+: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions
MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs…
STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca
MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson…
Johnson & Johnson antiviral pill for dengue shows early efficacy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Roche buys Telavant from Roivant for $7 billion, gaining bowel disease drug candidate
Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a…
STAT+: Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus…
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro
As demand for weight-loss treatments intensifies, Eli Lilly has filed a complaint with the U.S….
Opinion: STAT+: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients
Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices…
STAT+: Pharmacists can make shortage drugs, but at what cost?
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in…